“It’s truly fulfilling to see strategy translate into execution that enables patient access to game-changing innovations. Quorum continues to be at the forefront of developing novel and unique approaches that address the dynamic and ever-evolving reimbursement landscape.”
Mr. Scott supports client engagements by providing expertise across the commercialization continuum. He works with clients to develop strategies through evidence development, KOL engagement, and identifying customer drivers of product utilization. He leads many of the firm’s engagements for our advanced diagnostics clients, as well as practice areas focusing on commercialization planning and pricing strategies. Mr. Scott has supported dozens of pre-launch products across Marketing, Sales Ops, and Managed Care.
Mr. Scott has worked across numerous therapeutic areas, including extensive experience in oncology and ophthalmology. Additional disease spaces include cardiology, neurology, infectious disease, and gastroenterology. Product experience spans pharmaceuticals, medical devices, and diagnostics; both blockbuster status, as well as niche products with orphan indications. Mr. Scott is also a frequent contributor to Quorum’s Diagnostics Reimbursement Quarterly Newsletter for molecular diagnostics.
Prior to joining Quorum Consulting, Mr. Scott worked in a variety of capacities supporting commercial organizations. He spearheaded a number of launch readiness engagements while at Campbell Alliance Consulting Group. He also held several roles in the commercial organization at Genentech.
Master of Bioscience, Claremont Colleges, Keck Graduate Institute of Applied Life Sciences
BA, Biological Sciences, Willamette University